China Resources Sanjiu is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products.
As China Resources Group consolidates and acquires the pharmaceutical industry (strategic business unit: China Resources Pharmaceutical Group Co., Ltd.), new varieties of China Resources Sanjiu are constantly being added. Judging from the first half of 2013, the existing products are relatively rich, and the OTC business covers nearly 10 sub-fields such as cold medicines, skin medicines, and gastrointestinal medicines. Prescription drug varieties cover anti-tumor and cardiovascular treatment areas. The company has 13 varieties with annual sales of over 100 million yuan. Among them, the 999 Ganmao Ling series has ranked first in the cold medicine market for five consecutive years; Sanjiu Weitai and 999 Piyanping are also at the forefront of OTC stomach medicines and skin medicines respectively. ; In the cough and phlegm category, 999 Powerful Loquat Dew ranked fifth in the cold and cough category of proprietary Chinese medicines in the 2012 over-the-counter drug product ranking statistics.
The "999" brand is a well-known trademark in China. It is a well-known brand in the minds of Chinese people, and its products have a high market share.
In 2012, China Resources Sanjiu achieved operating income of 6.891 billion yuan, net profit attributable to owners of the parent company (net profit attributable to shareholders of listed companies) of 1.014 billion yuan, and cash flow generated from operating activities. Net amount is 1.212 billion yuan. As of the end of 2012, the company's total assets were 8.6 billion yuan.
Correspondingly:
Currently, China Resources Sanjiu’s total market value is 18 billion yuan, stably remaining at the forefront of listed companies in the pharmaceutical industry. The listed company and its multiple manufacturing units are national high-tech enterprises. China Resources Sanjiu has been awarded the "Golden Bull Award for the Top 100 Chinese Listed Companies in 2008", the "Top 100 Most Valuable Chinese Listed Companies in 2008", the "Top 100 Chinese Pharmaceutical Industry in 2009", and the "Top 20 Most Competitive Pharmaceutical Listed Companies in China in 2010". "Strong" and other honors. In 2011, when the China Traditional Chinese Medicine Association released the first batch of credit evaluation results for the traditional Chinese medicine industry, China Resources Sanjiu was awarded the AAA-level credit honor of a traditional Chinese medicine enterprise and topped the list.
After more than 20 years of unremitting efforts Through hard work, especially since it was merged into China Resources Group in 2007, China Resources Sanjiu has gradually developed into a large domestic pharmaceutical listed company.
In 2012, the "2012 China's Most Powerful Pharmaceutical Companies" was released by WPP, the world's second largest communication services group. In the "Top 50 Most Valuable Brands" list, the "999" brand was once again selected. This time, three pharmaceutical brands, "999", Yunnan Baiyao, and Tong Ren Tang, are located in Bao'an District, Shenzhen. The "China Resources Sanjiu Pharmaceutical Industrial Park" in Guanlan High-tech Industrial Park was officially completed and put into operation on May 8, 2008. The first phase of the project covers an area of ??110,000 square meters and has multiple production facilities such as granules, creams, and pills. workshops and fully automated elevated three-dimensional warehouses. In 2012, the second phase of the project was completed, and China Resources Sanjiu's headquarters, R&D division, sales company and other departments were moved to the Guanlan base (in the industrial park) from the north side of the original Beihuan Avenue.
China Resources Sanjiu has improved the composition of the board of directors, and the core role of the board of directors has been gradually strengthened. The company’s board of directors has established independent directors and external directors.
The board of directors has established an audit committee and a remuneration and assessment committee. The "Strategy and Investment Committee" is being established. The professional committee plays an active role in the medium and long-term motivation of employees and the development of internal audit work; the company's board of directors grants daily operation and management authority to the managers, and major matters such as investment are handled by the board of directors or The general meeting of shareholders makes decisions and gives full play to the core function of the board of directors in operating decision-making.
In June 2009, China Resources Sanjiu launched a risk management project to manage the risks (internal control) of key business processes of the company and its subsidiaries. The company conducts a comprehensive review of the system to investigate, prevent and control company risks. The company further improves the company's standard governance level by building a comprehensive risk management system.
CR Sanjiu introduced the 6S strategic management system, continuously improved budget management, and formulated a comprehensive budget management system. It is strategy-oriented and based on business strategy to comprehensively manage operating, capital expenditure, financial and other budgets. , better controlled costs and improved the efficiency of capital use.
In order to further enhance the core competitiveness of the company, China Resources Sanjiu continues to focus on its main business.
The first is to do subtraction. After China Resources Sanjiu's strategic positioning was clear, it further focused on its main business. Since 2008, it has divested non-main businesses such as real estate, food, pharmaceutical distribution, and retail;
The second is to make additions. Through extended mergers and acquisitions, the company has continuously increased its share of the main business, and has successively acquired pharmaceutical companies in Huangshi, Nanchang, Huaibei and other places; in 2011, driven by the group, it integrated the natural medicine division of Beijing Pharmaceutical Group. The proportion of the company's pharmaceutical manufacturing business in operating income increased from 57% in 2008 to 86% in 2011. On May 6, 2011, China Resources Sanjiu Pharmaceutical Co., Ltd. and the China Academy of Chinese Medical Sciences signed a letter of intent for cooperation in Beijing. The two parties* ** builds an industrialized production base and ** cooperates with the construction of medical institutions and reaches a cooperation intention: China Resources Sanjiu will integrate Beijing Huashen Pharmaceutical Co., Ltd. and the China Academy of Chinese Medical Sciences Experimental Pharmaceutical Factory to establish a new company in Beijing, and China Resources Sanjiu plans to invest More than 150 million yuan, holding 55% of the new company's equity. China Resources Sanjiu's investment is mainly used to build an industrialized production base in Daxing Industrial Park.
Strategic planning tips for 2011-2015: Determined to become a leader in the OTC market and an innovator in the traditional Chinese medicine prescription drug market through five years of hard work, and its market share will be among the forefront of China's pharmaceutical industry.
CR Sanjiu’s mission, vision and core values: The company advocates the core corporate values ??of “care, responsibility, and excellence”, cares for public health, fulfills social responsibilities, pursues outstanding performance, focuses on pharmaceutical manufacturing, and builds trust. brand, and build China Resources Sanjiu into a listed company that maximizes shareholder value and employee value.
The company was approved by the former State Economic and Trade Administration Commission Guojingmaoqigai [1999] No. 134 on March 2, 1999, in accordance with the relevant laws of the People's Republic of China and the People's Republic of China, and was established by Shenzhen Sanjiu Pharmaceutical Co., Ltd., Sanjiu Enterprise Group (Shenzhen Southern Pharmaceutical Factory), Shenzhen Jiuxian Bioengineering Co., Ltd., Shenzhen Xiandaming Property Management Co., Ltd. and Huizhou Renxing Industry and Trade Co., Ltd. serve as the sponsors to initiate A joint stock limited company established. The company was approved by the China Securities Regulatory Commission in the form of Zheng Jian Fa Zi [1999] No. 142, and issued 200 million RMB ordinary shares in November 1999, and was officially listed on the Shenzhen Stock Exchange on March 9, 2000. trade. In 2009, the company's Chinese name was changed from "Sanjiu Medical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd."; its English name was changed from "Sanjiu Medical & Pharmaceutical Co., Ltd." to "China Resources Sanjiu Medical & ;Pharmaceutical Co., Ltd.". The stock abbreviation was changed from "Sanjiu Pharmaceutical" to "China Resources Sanjiu". On February 11, 2010, with the approval of the Shenzhen Municipal Administration for Market Regulation, the company's name was officially changed to "China Resources Sanjiu Pharmaceutical Co., Ltd." Upon application by the company and approval by the Shenzhen Stock Exchange, starting from February 24, 2010, the company's securities abbreviation was changed from "Sanjiu Pharmaceutical" to "China Resources Sanjiu"; its English abbreviation was changed to "CR Sanjiu". When the company was listed, its business scope was: development, production, and sales of drugs, health products, and medical devices; development, transfer, and services of related technologies; medical and health care services.
In 2001, as reviewed and approved by the company's first extraordinary general meeting of shareholders in 2001, the company's business scope was changed to: development, production, and sales of drugs; development, transfer, and services of related technologies; machinery required for production Import business of equipment and raw materials; export of self-produced products (except for goods and technologies that are restricted by the state or prohibited from import and export).
To put it simply, it is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. The company has four major pharmaceutical business modules: OTC (over-the-counter drugs), prescription Chinese medicines, non-fried Chinese medicines, antibiotics and general medicines, supplemented by packaging and printing, medical services and other related businesses. Sanjiu Pharmaceutical Co., Ltd. was approved by Shenzhen Sanjiu Pharmaceutical Co., Ltd. in accordance with the relevant laws of the People's Republic of China and the People's Republic of China on March 2, 1999 by the former State Economic and Trade Administration Document Guojingmaoqigai [1999] No. 134. Pharmaceutical Co., Ltd. (hereinafter referred to as "Sanjiu Pharmaceutical") is the main sponsor, Sanjiu Enterprise Group (Shenzhen Nanfang Pharmaceutical Factory) (hereinafter referred to as "Sanjiu Group"), Shenzhen Jiuxian Bioengineering Co., Ltd., Shenzhen Xian Daming Property Management Co., Ltd. and Huizhou Renxing Industry and Trade Co., Ltd. are the sponsors and a joint-stock company established by sponsorship.
And registered with the State Administration for Industry and Commerce on April 21, 1999, and received a corporate business license. When the company was established, the registered capital was RMB 553 million. The company was approved by the China Securities Regulatory Commission in the form of Zheng Jian Fa Zi [1999] No. 142, and issued 200 million RMB ordinary shares in November 1999, and was officially listed on the Shenzhen Stock Exchange on March 9, 2000. After the transaction, the company's registered capital was RMB 753 million. On June 11, 2003, the Company implemented the plan of converting capital reserve funds into 3 shares for every 10 shares approved by the 2002 Annual General Meeting, and the registered capital increased by RMB 225.9 million.
As of December 31, 2007, the company's total share capital was 978.9 million shares, but the industrial and commercial registration change procedures for capital increase have not yet been completed. The company has established a general meeting of shareholders, a board of directors and a board of supervisors. When the company was listed, Shenzhen Sanjiu Pharmaceutical Co., Ltd. held 62.72% of the company's shares and was the company's controlling shareholder.
On April 16, 2008 and June 16, 2008, the State-owned Assets Supervision and Administration Commission of the State Council and the Ministry of Commerce respectively approved the transfer of 84,462,520 state-owned legal person shares of the company held by Sanjiu Enterprise Group. The shareholding entities of the company and the 613,937,480 state-owned legal person shares of the company held by Shenzhen Sanjiu Pharmaceutical Co., Ltd. were uniformly changed to New Sanjiu Holdings Co., Ltd. (now renamed China Resources Pharmaceutical Holdings Co., Ltd.).
On November 27, 2008, the company’s controlling shareholder was changed to China Resources Pharmaceutical Holdings Co., Ltd. China Resources Sanjiu Pharmaceutical Industrial Park: Located in Guanlan High-tech Industrial Park, Baoan District, Shenzhen City, it was officially completed and put into production on May 8, 2008. The first phase covers an area of ??110,000 square meters and has granules, creams, pills, etc. Multiple modern production workshops and fully automated elevated three-dimensional warehouses integrate R&D, production and logistics distribution. It is a large-scale traditional Chinese medicine industry base in China.
The completion of China Resources Sanjiu Pharmaceutical Industrial Park has comprehensively promoted the modernization of traditional Chinese medicine, new product development, production capacity expansion, and product quality improvement of listed companies. The second phase of the project was completed in 2012, and all the company's other related pharmaceutical production and supporting facilities were moved in. The current office location has also been moved from Futian District, Shenzhen City to Longhua New District, Shenzhen City.
Facing the future, China Resources Sanjiu has established a development strategy, which is to take brand OTC as the core business, take Chinese medicine prescription drugs and non-fried Chinese medicine as fast-growing key businesses, integrate antibiotics and general medicine business, and enter the third terminal. On the basis of developing large varieties, we will continue to enrich product categories through external mergers and acquisitions, purchases, development, etc., gradually implement category planning, and expand business scale. With brand operation and channel control capabilities as its core advantages, it will increase investment in R&D and technological transformation, improve product functions and quality, and form a value creation system that uses marketing to drive R&D and production to sustain growth.
In order to ensure the realization of strategic goals, the company is establishing a highly centralized operating system with business modules as analysis and management units, marketing, production, R&D, fund management and brand management.